CASI Pharmaceuticals Aktie

Casi Pharmaceuticals announced that David Cory will step down as CEO and director effective March 31, 2026. After his departure, Dr. Wei‑Wu He, Ph.D., currently executive chairman of the board, will assume the role of principal executive officer. The SEC filing gives no reasons for the leadership change; the company is developing the monoclonal anti‑CD38 candidate CID‑103 in the clinical stage. » Plus sur de.investing.com

CASI Pharmaceuticals received convertible notes in a private placement totaling $20 million from ETP Global III Fund LP (a partnership controlled by Dr. Wei‑Wu He) to finance the monoclonal anti‑CD38 therapeutic CID‑103, in particular a Phase‑1 study on antibody‑mediated rejection (AMR) of kidney transplants in China and the development of a subcutaneous formulation. The notes will be issued in tranches, have a 36‑month term, carry a 12% annual interest rate and are convertible from day 91 at a price between $1 and $2 per share. CASI continues to face a strained balance sheet and a Nasdaq delisting decision, but has recently reported revenue growth and is recruiting patients for additional Phase‑1 studies. » Plus sur de.investing.com